Intelence

Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretroviral treatment-experienced adults, in combination with a boosted protease inhibitor and other antiretrovirals.

Etravirine is the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be launched in 10 years and it is the first NNRTI to show antiviral activity in treatment experienced adult patients resistant to NNRTIs.

Intelence has been authorised under a ‘conditional approval' scheme which means new information on etravirine will be reviewed yearly and the SPC updated as necessary.

View Intelence drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.